Li-Fraumeni & TP53: Understanding and Progress (LiFT UP)

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Genetic
Study Type: Observational
SUMMARY

The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Individuals with a TP53 pathogenic or likely pathogenic variant identified in blood or saliva,

• Individuals with variants of uncertain significance in TP53 may be eligible at the PI's discretion,

• Blood relatives of individuals with a TP53 variant, who may be presumed obligate carriers or healthy controls,

• Individuals who meet Classic or Chompret LFS criteria whether or not they have a TP53 gene variant,

• Individuals may enroll their deceased relatives in the study.

• Individuals with a known TP53 variant that is not LFS, but rather ACE, CHIP, or mosaicism.

• Individuals participating in other LFS studies can still enroll in LiFT UP. Investigators may be collaborators.

Locations
United States
Massachusetts
Boston Children's Hospital
RECRUITING
Boston
Brigham and Women's Hospital
RECRUITING
Boston
Judy E. Garber
RECRUITING
Boston
Contact Information
Primary
Judy E Garber, MD, MPH
jegarber@partners.org
617-632-5770
Backup
Sophie Cahill, BS
Sophie_Cahill@DFCI.HARVARD.edu
617-632-4795
Time Frame
Start Date: 2020-09-15
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 1500
Treatments
Variant in the TP53 Gene in blood or saliva
Variant in the TP53 gene found on a blood or saliva test, have a relative with a variant in the TP53 gene, or because participant meets genetic testing criteria for Li-Fraumeni Syndrome (LFS) based on personal or family cancer history
Related Therapeutic Areas
Sponsors
Leads: Dana-Farber Cancer Institute
Collaborators: Baylor College of Medicine, National Cancer Institute (NCI), City of Hope Medical Center

This content was sourced from clinicaltrials.gov